Abstract: The disclosure discloses a method and markers for assessing the risk of having colorectal cancer for an individual by a stool sample. The method includes: detecting expression levels of a first microRNA and a second microRNA in the stool sample; and assessing the risk of having colorectal cancer for the individual based on a ratio between the expression levels of the first microRNA and the second microRNA. Here, the first microRNA is miR-223, miR-25, or miR-93, and the second microRNA is miR-221, miR-222, miR-21, miR-93, miR-141, miR-200c, miR-191, miR-17, miR-148a, miR-106a, miR-195, miR-20a, miR-181b, miR-145, miR-155, miR-106b, miR-24, miR-19b, miR-130b, or miR-18a. When the first microRNA is miR-93, the second microRNA is miR-17, miR-106a, miR-195, miR-20a, miR-181b, miR-155, miR-24, miR-19b, or miR-18a.

Abstract: The disclosure discloses a method and markers for assessing the risk of having colorectal cancer by a blood sample obtained from an individual. The assessment method includes the steps of: detecting expression levels of a first microRNA and a second microRNA in the blood sample; and assessing the risk of having colorectal cancer for the individual based on a ratio between the expression levels of the first microRNA and the second microRNA. Here, the first microRNA is miR-221, miR-92a, miR-15a, miR-24, miR-18a, miR-191, miR-128, or miR-223, and the second microRNA is miR-10b, miR-100, miR-29a, miR-126, miR-139, miR-31, miR-145, or miR-155. When the first microRNA is miR-128, the second microRNA is miR-10b, miR-100, miR-29a, miR-126, miR-139, miR-31, or miR-145.